- Home
- LWAY vs TRVI Comparison
LWAY vs TRVI Comparison
Compare LWAY & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LWAY
- TRVI
- Stock Information
- Founded
- LWAY 1986
- TRVI 2011
- Country
- LWAY United States
- TRVI United States
- Employees
- LWAY N/A
- TRVI N/A
- Industry
- LWAY Packaged Foods
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- LWAY Consumer Staples
- TRVI Health Care
- Exchange
- LWAY Nasdaq
- TRVI Nasdaq
- Market Cap
- LWAY 355.7M
- TRVI 363.7M
- IPO Year
- LWAY 1987
- TRVI 2019
- Fundamental
- Price
- LWAY $22.21
- TRVI $4.60
- Analyst Decision
- LWAY Hold
- TRVI Strong Buy
- Analyst Count
- LWAY 1
- TRVI 8
- Target Price
- LWAY N/A
- TRVI $9.31
- AVG Volume (30 Days)
- LWAY 37.9K
- TRVI 739.7K
- Earning Date
- LWAY 03-19-2025
- TRVI 03-19-2025
- Dividend Yield
- LWAY N/A
- TRVI N/A
- EPS Growth
- LWAY 59.90
- TRVI N/A
- EPS
- LWAY 0.86
- TRVI N/A
- Revenue
- LWAY $181,979,000.00
- TRVI N/A
- Revenue This Year
- LWAY $19.38
- TRVI N/A
- Revenue Next Year
- LWAY $11.79
- TRVI N/A
- P/E Ratio
- LWAY $25.85
- TRVI N/A
- Revenue Growth
- LWAY 18.27
- TRVI N/A
- 52 Week Low
- LWAY $9.93
- TRVI $2.30
- 52 Week High
- LWAY $28.61
- TRVI $5.05
- Technical
- Relative Strength Index (RSI)
- LWAY 45.67
- TRVI 62.80
- Support Level
- LWAY $21.89
- TRVI $3.93
- Resistance Level
- LWAY $23.58
- TRVI $4.14
- Average True Range (ATR)
- LWAY 0.82
- TRVI 0.29
- MACD
- LWAY 0.05
- TRVI 0.06
- Stochastic Oscillator
- LWAY 46.69
- TRVI 64.82
About LWAY Lifeway Foods Inc.
Lifeway Foods Inc is engaged in manufacturing probiotic, cultured, functional dairy health food products. Its primary product is drinkable kefir which is a cultured dairy product. Its product categories are Drinkable Kefir which is the key revenue-driving product, European-style soft cheeses, Cream, ProBugs, Frozen Kefir and Other dairy. The company manufacture and market products under the Lifeway and Fresh Made brand names, as well as under private labels on behalf of customers. It sells the products primarily through direct sales force, brokers, and distributors.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.